All In Biotech

Drug Trial Radar · NCT04762602

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

42

Actual

Start

Feb 28, 2021

Primary completion

Feb 27, 2025

Study completion Feb 27, 2025

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.

Conditions

  • Isocitrate Dehydrogenase Gene Mutation

Interventions

  • HMPL-306Drug

    Administered orally QD in a 28-day continuous dosing treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
  2. Part 1: Number of Patients With Dose-limiting Toxicities (DLTs)Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
  3. Parts 1 and 2: Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 43 months for Part 1

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Sarcoma Oncology Research Center

    Santa Monica, California

  • Emory University

    Atlanta, Georgia

  • University of Iowa

    Iowa City, Iowa

  • University of Kentucky

    Lexington, Kentucky

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer

    Pittsburgh, Pennsylvania

  • Houston Methodist

    Houston, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Hospital de la Santa creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.